Samsung Biologics

Last updated
Samsung Biologics Co., Ltd.
Company type Public
KRX: 207940
Industry Biopharmaceuticals
Founded2011;13 years ago (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim (president and CEO) [1]
RevenueIncrease2.svg KRW 3.69 trillion (2023) [2]
Increase2.svg KRW 1.11 trillion (2023) [2]
Owners
Number of employees
4,300 (2023)
Subsidiaries Samsung Bioepis
Korean name
Hangul
Revised Romanization Samseong Baiorojikseu
McCune–Reischauer Samsŏng Paiorojiksŭ
Website samsungbiologics.com

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

Contents

The company has partnered with pharmaceutical companies such as Pfizer, [3] GlaxoSmithKline, [4] Eli Lilly, [5] AstraZeneca [6] and Bristol-Myers Squibb. [7]

History

Facilities & Expansion

Founded in 2011, [8] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023. [9] [10] [11] In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity. [12]

Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey [13] and San Francisco [14] to more closely support U.S. biopharmaceutical companies across both coasts.

Notable Partnerships

As of June 2024, Samsung Biologics' CEO John Rim reported active partnerships with 16 of the top 20 largest biopharmaceutical companies. [15] [16] This includes early deals with Roche [17] and Bristol-Myers Squibb [18] in 2013, through to large partnerships during and after the pandemic. In 2020, GSK and Samsung Biologics signed the first of two major agreements: a $231 million, eight-year deal to manufacture biological therapies, including the lupus drug Benlysta. [19] Two years later, a second $296 million deal was signed. [20]

During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax. [21] [22] The company was also contracted to manufacture Eli Lilly's COVID-19 antibody therapeutic [23] and AstraZeneca's long-acting antibody therapeutic as part of a larger multi-product deal. [24]

In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million. [3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4. [25]

Along with Big pharma partnerships, the company has engaged with smaller development-stage companies. In 2023, Samsung Biologics announced a multi-year agreement with European venture capital firm Kurma Partners to support its portfolio companies through development, manufacturing, and de-risking services. [26] In February 2024, Samsung Biologics announced a partnership agreement with LigaChem (formerly LegoChem) Biosciences to provide antibody development and drug substance manufacturing services to support LigaChem's antibody-drug conjugate (ADC) pipeline. [27]

Business Ventures

In 2012, it established Samsung Bioepis, a biosimilar medicine developer, as a joint venture with Biogen. [28] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion. [29]

In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T. [30] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.

Platforms

Samsung Biologics has developed a range of proprietary technologies for biologics development. This includes S-CHOice, a cell line expression technology introduced in 2020. [31] In 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform, [32] and its DEVELOPICK platform, a service that selects candidate materials for new drugs.

Sustainability

Samsung Biologics published its first annual sustainability report in June 2021. It was added to the Dow Jones Sustainability World Index later that year. [33]

Samsung Biologics was awarded the Sustainable Market Initiative's 2022 Terra Carta Seal, which recognizes global companies driving innovation and action towards the creation of genuinely sustainable markets. [34]

In 2023, Samsung Biologics received both a leadership A- score from the Carbon Disclosure Project (CDP) [35] and an EcoVadis Platinum Sustainability Rating, [36] placing the company in the top one percent of over 100,000 companies assessed by EcoVadis.

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Daiichi Sankyo</span> Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

<span class="mw-page-title-main">Amneal Pharmaceuticals</span> American publicly traded generics and specialty pharmaceutical company

Amneal Pharmaceuticals, Inc. is an American publicly traded generics and specialty pharmaceutical company. The company is headquartered in Bridgewater, New Jersey.

<span class="mw-page-title-main">Novavax</span> American biotechnology company

Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19.

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.

<span class="mw-page-title-main">Operation Warp Speed</span> US program to accelerate COVID-19 vaccine efforts

Operation Warp Speed (OWS) was a public–private partnership initiated by the United States government to facilitate and accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics. The first news report of Operation Warp Speed was on April 29, 2020, and the program was officially announced on May 15, 2020. It was headed by Moncef Slaoui from May 2020 to January 2021 and by David A. Kessler from January to February 2021. At the end of February 2021, Operation Warp Speed was transferred into the responsibilities of the White House COVID-19 Response Team.

<span class="mw-page-title-main">BioNTech</span> German biotechnology company

BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.

<span class="mw-page-title-main">History of COVID-19 vaccine development</span> Scientific work to develop a vaccine for COVID-19

SARS-CoV-2, the virus that causes COVID-19, was isolated in late 2019. Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. Since 2020, vaccine development has been expedited via unprecedented collaboration in the multinational pharmaceutical industry and between governments. By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection. According to the Coalition for Epidemic Preparedness Innovations (CEPI), the geographic distribution of COVID‑19 vaccine development shows North American entities to have about 40% of the activity, compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa.

<span class="mw-page-title-main">COVID-19 vaccination in South Korea</span> Plan to immunize against COVID-19

COVID-19 vaccination in South Korea is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.

BIOTECanada, previously the Industrial Biotechnology Association of Canada, is a Canadian biotechnology industry association based in Ottawa, Ontario. It is an industry-funded membership organization composed of over 250 national and international pharmaceutical and gene therapy companies, medical device manufacturers, agricultural science businesses, law firms, academic institutions, research and development networks, advertising agencies, insurance companies and financial services firms.

<span class="mw-page-title-main">AION Labs</span>

AION Labs is an Israeli venture studio focused on the adoption of artificial intelligence (AI) and machine learning (ML) in pharmaceutical discovery and development processes.

References

  1. ↑ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
  2. 1 2 "Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
  3. 1 2 biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  4. ↑ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
  5. ↑ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
  6. ↑ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
  7. ↑ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
  8. ↑ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  9. ↑ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  10. ↑ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  11. ↑ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  12. ↑ "Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II". BioPharm International. 21 March 2023.
  13. ↑ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  14. ↑ Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
  15. ↑ Ha-Nee, Shin (7 June 2024). "Business soars for Korean pharma as U.S. cuts ties with Chinese partners". Korea JoongAny Daily.
  16. ↑ Ahn, Dae-Kyu (7 June 2024). "Samsung Biologics eyes windfall gain amid US-China row". The Korean Economic Daily.
  17. ↑ Tyler, Dominic (24 October 2013). "Roche signs biologics partnership with Samsung". PMLiVE.
  18. ↑ Thomas, Felicity (20 September 2023). "Samsung Biologics Expands Strategic Manufacturing Agreement with Bristol Myers Squibb". Pharmaceutical Technology.
  19. ↑ Liu, Angus (22 May 2020). "GlaxoSmithKline hands Samsung Biologics $231M to scale up manufacturing". Fierce Pharma.
  20. ↑ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma.
  21. ↑ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
  22. ↑ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
  23. ↑ Stanton, Dan (23 November 2020). "Samsung Bio in $150m deal to make COVID antibodies for Lilly". BioProcess International.
  24. ↑ Keenan, Joseph (14 December 2021). "Samsung Biologics, AstraZeneca expand manufacturing partnership to add COVID and cancer therapies". Fierce Pharma.
  25. ↑ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
  26. ↑ Nelson, Millie (30 October 2023). "Samsung Biologics strikes manufacturing and development deal with Kurma". BioProcess International.
  27. ↑ Keenan, Joseph (7 February 2024). "Samsung Biologics, LegoChem partner to propel ADC development and production". Fierce Pharma.
  28. ↑ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  29. ↑ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  30. ↑ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". The Korea Economic Daily. 30 March 2022.
  31. ↑ Jeong-yeo, Lim (5 August 2020). "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  32. ↑ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  33. ↑ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.
  34. ↑ Eckford, Catherine. "2022 Terra Carta Seal: three pharma companies awarded". European Pharmaceutical Review.
  35. ↑ Byung-yeul, Baek (13 February 2024). "Samsung Biologics recognized for response to climate change". The Korea Times.
  36. ↑ Choi, Jasmine (23 January 2024). "Samsung Biologics Achieves Top 'Platinum' Rating in EcoVadis ESG Evaluation". Business Korea.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.